Reducing Allostatic Load in Depression and Anxiety Disorders: Physical Activity and Yoga Practice as Add-On Therapies

Luciana D’Alessio1,2*, Guido Pablo Korman3, Mercedes Sarudiansky3, Laura Ruth Guelman4, Laura Scévola2, Alejandra Pastore5, Amilcar Obregón5 and Emilio J. A. Roldán5

1 Universidad de Buenos Aires, Facultad de Medicina, IBCN-CONICET, Buenos Aires, Argentina, 2 Universidad de Buenos Aires, Hospital Ramos Mejía, Buenos Aires, Argentina, 3 Universidad de Buenos Aires, Facultad de Psicología, CAEA-CONICET, Buenos Aires, Argentina, 4 Universidad de Buenos Aires, Facultad de Medicina, CEFYBO-CONICET, Buenos Aires, Argentina, 5 Dirección Médica y Científica, Gador SA, Buenos Aires, Argentina

The allostatic load (AL) index constitutes a useful tool to objectively assess the biological aspects of chronic stress in clinical practice. AL index has been positively correlated with cumulative chronic stress (physical and psychosocial stressors) and with a high risk to develop pathological conditions (e.g., metabolic syndrome, cardiovascular pathology, inflammatory disorders) and the so-called stress-related psychiatric disorders, including anxiety and depressive disorders. Chronic stress has negative effects on brain neuroplasticity, especially on hippocampal neurogenesis and these effects may be reversed by antidepressant treatments. Several evidences indicate that non-pharmacological interventions based on physical activity and yoga practice may add synergizing benefits to classical treatments (antidepressant and benzodiazepines) for depression and anxiety, reducing the negative effects of chronic stress. The aim of this review is to provide a general overview of current knowledge on AL and chronic stress in relation to depression and anxiety, physical activity and yoga practice.

Keywords: chronic stress, neuroplasticity, neurogenesis, hippocampus, cortisol, noradrenaline, antidepressants, benzodiazepines

INTRODUCTION

The concept of allostatic load (AL) index, has been introduced by Bruce McEwen and Stellar in 1993 to objectively assess the biological consequences of chronic stress in the body and the brain (1). Psychosocial factors related to poverty and health risk behaviors across the lifespan have been associated with higher AL index (2, 3). AL index has been positively correlated with cumulative chronic stress (physical and psychosocial stressors) and with a high risk to acquire medical conditions (e.g., metabolic syndrome, cardiovascular pathology, inflammatory disorders) (4–8). Moreover, chronic stress and AL overload may contribute to the expression of the so-called stress-related psychiatric disorders, especially represented by anxiety and depressive disorders (5, 9–12). Furthermore, chronic stress through hypercortisolemia can induce negative effects on brain...
neuroplasticity, especially on hippocampal neurogenesis (13–16) and these effects may be reversed by antidepressant treatments (17, 18).

Evidences based on experimental data and studies in human patients indicate that physical activity and yoga practice might bring about benefits not only in adult hippocampal neurogenesis and neuroplasticity (19), but also on stress related psychiatric symptoms (anxiety and depression) (20, 21) as well as on AL index (22, 23). Non-pharmacological interventions and classical treatments (psychotherapeutic and pharmacological approaches) may have synergistic effects on brain function and clinical symptoms which helps building the idea of managing depression and anxiety disorders using combined treatments (19, 21). The implementation of these strategies as add-on therapy may optimize the pharmacological treatment reducing the risk of adverse side effects. Therefore, the aims of this review are to provide an overview of the biology aspects of AL and chronic stress in reference to depression and anxiety, and to describe the current knowledge on the non-pharmacological interventions based on physical activity and yoga practice upon AL, depression and anxiety.

THE ALLOSTASIS CONCEPT AND THE ALLOSTATIC LOAD INDEX

The term allostasis refers the ability to achieve stability through changes in response to stress and/or stressful events (4). The most important systems involved in the stress response are the hypothalamic-pituitary-adrenal (HPA) axis, the autonomic nervous system and the inflammatory system, with their respective biochemical mediators, the glucocorticoids, the catecholamines (adrenaline and noradrenaline) and the cytokines. These compounds produce physiologic effects that are adaptive in the short term, however they can be harmful in the long term (chronic stress) (4, 5, 10, 13).

The AL index was proposed with the aim of measuring the cumulative influence of stress on health through a series of clinical and biochemical indicators of the main systems potentially affected (4, 6). Essentially, the AL index constitutes a marker of cumulative biological risk of chronic stress which describes the additive effects of multiple clinical situations that may accelerate the vulnerability to diseases reducing resilience (9, 10, 24–26). The AL index was found to be a good predictor of mortality and physical functioning (27). The clinimetric definition of AL overload, firstly introduced by Feinstein in 1987 to define clinical measurements related to chronic stress, was recently described by Fava and McEwen et al. in 2019 (27). These authors proposed two main criteria: the presence of a current source of distress added to previous symptoms or functioning impairment (27).

AL index includes different biological markers divided in two main groups; 1-Primary mediators: represented by stress hormones (adrenaline, noradrenaline, and cortisol) in combination with inflammatory cytokines (e.g., interleukin-6, tumor necrosis factor), 2- Secondary mediators: represented by biomarkers of metabolic, cardiovascular, and immune systems that compensate primary mediators alterations [e.g., insulin, glucose, total cholesterol, high density lipoprotein cholesterol, triglycerides, visceral fat depositing, systolic and diastolic blood pressure, fibrinogen, c-reactive protein; (2, 8, 28)]. Different authors have applied the AL index in population-based studies and/or in clinical trials and studied the association with depression and anxiety disorders (8, 11, 28–32). Table 1 summarizes the AL index and the cut off points analyzed in a

| TABLE 1 | Allostatic load parameters and cut-off points. |
|--------------------------------------------|---------------------------------------------|
| **Affected systems**                      | **Allostatic Load Parameters**              | **Cut-off points (for AL index)** |
| **Primary mediators**                     |                                            |                               |
| HPA-Cortisol                              | Cortisol                                   | >32 nM Salivary               |
|                                          | DHEA (dehydro-epi-androsterone)            | <80 ng/ml in men              |
|                                          | Auto-nomic System                           |                               |
|                                          | Noradrenaline                               | >100 pg/ml (plasma)           |
|                                          | MHPG (methoxy-hydroxy-phenyl-glycol)        | >2,750 nM (salivary)          |
| **Secondary mediators**                   |                                            |                               |
| Cardiovascular                            | Systolic blood pressure                     | >140 mmHg                     |
|                                          | Diastolic blood pressure                    | >90 mmHg                      |
| Metabolism: Lipids and adipose tissue deposition | Body Mass Index                           | >25                           |
|                                          | Waist-hip ratio                            | >1 in men                     |
|                                          | Total cholesterol                          | >200 mg/dl (plasma)           |
|                                          | LDL (low density lipoprotein)              | >120 mg/dl (plasma)           |
|                                          | HDL (high density lipoprotein)             | <37 mg/dl (plasma)            |
|                                          | Total cholesterol/HDL ratio                | >3.5 mg/dl (plasma)           |
| Metabolism: Glucids, proteins and renal function | Glycated hemoglobin                      | >6 mg/dl (plasma)             |
|                                          | Creatinine                                 | >1.2 mg/dl (plasma)           |
|                                          | Albumin                                    | <3.5 g/dl (plasma)            |
| Immune System                             | C-reactive protein                         | >7.1 mg % (plasma)            |
|                                          | Fibrinogen                                 | >400 mg/dl (plasma)           |
previous study performed by our group, in patients with general anxiety disorder (12, 32).

**DEPRESSION, ANXIETY, AND AL**

The relationship between chronic stress, depression and anxiety has been extensively described (5, 9, 10, 13). Experimental models showed that stress hormones (glucocorticoids) acting on the brain, may modify emotional arousal, predisposing to depression- and anxiety-like behavior (33). Furthermore, chronic stress models in rodents can cause changes in brain neuroplasticity and changes in behavior consistent with depressive- and anxiety-like symptoms (5, 9, 10, 13, 33–36).

In humans, the administration of exogenous glucocorticoids may produce psychiatric adverse effects, such as steroid psychoses and depression. These symptoms may be blocked by the glucocorticoid antagonist mifepristone (37, 38). In patients with major depressive disorder, cortisol levels are elevated, the diurnal rhythm is distorted and the HPA axis is resistant to suppression by dexamethasone (9, 33, 37, 38). Moreover, higher AL index has been associated with higher levels of depressive symptoms in many studies (8, 11) (28–30, 39). Compared with patients with personality disorders, emergency psychiatric patients primarily diagnosed with bipolar, depressive, or anxiety disorders showed altered AL parameters including cortisol, interleukin-6, systolic blood pressure, and heart rate (11). Also, higher AL index were significantly associated with depressive symptoms (29) showing variations according to sex, gender, race, and sociocultural factors (30, 31).

Cardiovascular parameters of AL index were frequently altered in patients with depression (11, 28, 29). Longitudinal cohort studies showed increase risk of cardiovascular morbidity and mortality among patients with comorbid depression (40). In a recent study, Gillespie et al. analyzed the role of AL and depression in relation to coronary heart disease. Greater depressive symptomatology was associated with higher metabolic, cardiovascular, and immune AL parameters, however coronary heart disease was associated to depression, only in male population (28). Obesity, metabolic abnormalities and higher expression of inflammatory markers were also frequently observed in patients with depression (23, 30, 41). Compared with age- and gender-matched control groups, individuals with major depression had higher metabolic syndrome prevalence, hyperglycaemia, and hypertriglyceridaemia (41).

Regarding anxiety, high levels of cortisol and CRH (corticotrophin releasing hormone), have been associated to fear states and anxiety-like behavior in experimental models (13, 33). Disturbances in the HPA with hypercortisolemia were reported among patients with anxiety disorders, in patients with panic disorder (42) and in patients with general anxiety disorder (32, 43). In addition, sympathetic hyperactivity with high levels of methoxyhydroxiphenilglicol (MHPG) (the main metabolite of noradrenaline) was also reported in patients with anxiety disorder (32, 44, 45).

Sex and age related differences in psychiatric symptoms and AL parameters were also described in the literature (28–30, 32, 46). Firstly, a higher prevalence and severity of depression and anxiety disorders has been reported in women compared to men (29, 32, 47). Biological differences have been proposed to explain such differences since experimental studies in rodents suggest sex differences in the neural remodeling pattern after stress (10, 48). However, psychosocial influences cannot be excluded as women are also more exposed to psychosocial stress and trauma (30, 49, 50). Women in fertile age are less prone to cardiovascular disease and mortality than men (28, 31, 51, 52). In a previous study of our group in patients with anxiety disorders, women showed higher anxiety levels than men, with a better profile in many individual AL variables, particularly cardiovascular (systolic blood pressure), obesity (body mass index), and lipids with higher HDL (high density lipoprotein cholesterol) levels (32). On the opposite, AL inflammatory parameters tended to be higher in women (30, 46, 52). Regarding age factors, elderly patients were more vulnerable to stress-related disorders and expressed higher levels of cumulative AL (2, 6, 7, 32).

**CHRONIC STRESS AND HIPPOCAMPAL NEUROPLASTICITY: THE ROLE OF ANTIDEPRESSANT TREATMENTS**

The hippocampus has been in the focus of stress research especially after the finding that glucocorticoid receptors are abundantly expressed in hippocampal cells (53). A large body of evidence in rodents demonstrated that chronic stress, via elevated levels of glucocorticoids, can affect both hippocampal structure and function (16, 33, 54) and can also induce depressive-like behavior (18). Adult hippocampal neurogenesis (the brain capacity to develop new neurons during adult life) (55), decrease with age and is especially affected by chronic stress (15, 56, 57).

Hippocampal structure and function might be altered in patients with depression. Reductions in hippocampal volume based on magnetic resonance imaging studies have been consistently documented in patients with major depression (58, 59). For example, patients suffering from recurrent depressive episodes showed lower hippocampal volume (60, 61). Similarly, in Cushing’s disease, the duration of the illness predicts a progressive reduction in the hippocampus volume, which was determined by structural magnetic resonance imaging (62). Besides, the atrophy of the hippocampus has also been reported among patients with anxiety-related disorders and post-traumatic stress disorder (63). Moreover, depression is a common comorbidity in patients with resistant temporal lobe epilepsy and hippocampal sclerosis (14, 64, 65).

In humans, adult hippocampal neurogenesis occurs in the hippocampal dentate gyrus, and newborn neurons can be produced from neural stem cells which can be classified based on their distinctive morphology as radial glia-like (66) and non-radial glial cells (67). Chronic physical stressors, chronic psychosocial stressors, and chronic unpredictable stressors, can inhibit one or more phases of the adult hippocampal
neurogenesis process (15). Neurotransmitters systems that regulate adult hippocampal neurogenesis might be affected by chronic stress: The enhance of glutamate release via NMDA (N-methyl-D-aspartate receptor), the reduction of GABA (Gamma aminobutyric acid) levels, the reduction of 5HT (serotonin) levels and the down regulation of 5HT1A (serotonin receptor 1A; stimulation of 5HT1A is pro-neurogenic), and the alterations in noradrenaline, dopamine, and endocannabinoids were described (18, 57, 68). Stress can also reduce the expression of neurotrophic factors involved in adult hippocampal neurogenesis regulation (e.g., brain-derived neurotrophic factor, insulin-like growth factor-1, neuregulin-1; 69, 70). Neurotrophic factors have been shown to increase adult hippocampal neurogenesis and also modulate antidepressant-related effects and behavior in experimental models (18, 71).

Adult hippocampal neurogenesis is involved in mediating the response to antidepressant drugs (18, 72). The suppression of adult hippocampal neurogenesis achieved by chronic stress can be prevented by administering antidepressants (72, 73) which reverse the inhibitory effect of stress after 3–4 weeks of treatment (time course of maturation for newly generated neurons) (17, 72–75). Antidepressants require of adult hippocampal neurogenesis mechanisms to be effective (57, 76) and involve the activation of glucocorticoid receptors in the hippocampus (77). The stimulation of adult hippocampal neurogenesis has been considered a promising property for identifying new antidepressant targets. At the moment almost all antidepressant treatments including pharmacotherapy and behavioral interventions, proved to stimulate adult hippocampal neurogenesis (15, 57, 78).

**CHRONIC STRESS AND ANXIETY: ROLE OF ANXIOLYTICS TREATMENTS**

During stress response sympathetic system is simultaneously activated with HPA system, and both noradrenaline and cortisol are released, amplifying the emotional response (4, 5, 10, 13). Anxiety has been proposed as an undifferentiated form of fear or rage, discharged by noradrenaline and cortisol (79). Anxiolytic drugs acting through a positive allosteric modulation of GABA-A receptor (benzodiazepines), reduce the sympathetic discharge leading to lower plasma levels of catecholamines (80–82) and lower salivary levels of MHPG (44, 45, 83, 84). Benzodiazepines, particularly those of high-potency such as alprazolam, have demonstrated anti-hypertensive pleiotropic properties in patients with high blood pressure without affecting the heart rate (81, 85). In our previous work (32), low doses of alprazolam during 12 weeks reduced anxiety levels and the total AL index. We observed a significant reduction on salivary levels of MHPG and on systolic blood pressure (12, 32). As well pharmacotherapy with benzodiazepines in association to psychotherapy demonstrated to be effective in reducing anxiety and AL parameters (86), the risk of inducing pharmacological dependence and/or cognitive adverse events should be considered requiring continuous monitoring (87–89).

**NON-PHARMACOLOGICAL STRATEGIES, PHYSICAL ACTIVITY, AND YOGA PRACTICE**

**Physical Activity**

Many studies based on experimental research in rodents demonstrated that physical activity interventions may promote hippocampal neuroplasticity, counteracting the negative effects of chronic stress on the brain (15, 19, 90–95). Models of aerobic exercise potently stimulate adult hippocampal neurogenesis, inducing higher rates of proliferation and/or survival of newborn cells (15, 90). Also, higher synaptic plasticity and higher levels of BDNF (Brain Derived Neurotrophic Factor), were observed in hippocampus, after voluntary and involuntary exercise (91, 92). Additionally, the use of combined treatments (e.g., aerobic exercise and antidepressant treatments), has stronger effect on depressive behavior and on BDNF up-regulating, than antidepressant treatment or aerobic exercise acting individually (93–95).

In humans, neuroimaging studies using MRI (Magnetic Resonance Image) demonstrated that physical activity increased the hippocampal volume and positively correlated with better performances on hippocampus dependent tasks (episodic memory) (96). Physical activity can enhance some indirect signs of neuroplasticity (e.g., increased cerebral blood flow or BDNF plasma concentration) (96). Plasma levels of BDNF have been proposed as a potential biomarker of depression treatment. Serum BDNF is decreased in depressed patients and can be normalized with antidepressant treatment together with moderate to intense physical activity (97, 98).

Physical activity has been considered a non-stigmatizing intervention with few side effects and has been associated with the relief of depression and anxiety symptoms in different studies (20, 21, 99, 100). Different types of physical activity (aerobic, stretching, leisure-physical activities, dance, yoga asanas), have been associated with lower depression and anxiety prevalence in population-based studies (23, 100–102), with a better outcome in patients with depressive disorders (103–106) and with lower scores of self-reported stress, anxiety, and depression scales in healthy subjects (107–109). Physical activity may prevent the development of depression during the follow up according prospective studies (23, 100, 102), can reduce de the risk of anxiety (110) and may enhance the cognitive performance (97) contributing with antidepressant drugs and/or cognitive-behavioral therapy (111). In a meta-analysis of relevant randomized controlled clinical trials, aerobic exercise showed moderate to large effects for patients with major depression and favoured over classical psychological treatments or antidepressants drugs (20). Physical activity may act as an adjunctive treatment to traditional medication and psychotherapy, resulting in a more effective approach toward relief of psychiatric symptoms and AL (19, 20, 99, 105).

Table 2 resumes the main recent studies that have analyzed physiological AL parameters and the effects of physical activity (and/or yoga asanas) on depression and anxiety outcome. All resumed studies, population-based studies and clinical trials,
found a positive effect on depression and anxiety symptoms outcome in healthy subjects and in patients with depression. Although the total AL index was not measured, some of these studies analyzed certain AL parameters outcome. Obesity factors were positively associated with depression and negatively with physical activity (23). A lower fitness level in cardiopulmonary exercises was observed in patients with depression (104). Minor resting pulse was associated with physical activity and lower risk to develop depression in healthy subjects (100). Also, lower heart rate and diastolic blood pressure and higher HDL cholesterol, were observed among inpatients with major depressive disorder who underwent to a physical activity-training program (105).

Regarding the effects of physical activity on AL parameters sex differences were also reported (106, 112). Women showed higher levels of c-reactive protein, which positively correlated with measures of adiposity and inversely associated with fitness,

| Study                  | Type of study                        | Study participants | Physical activity                                                                 | Concomitant treatment | AL parameters measured                                                                 | Depression/Anxiety outcome | Main conclusion                                                                 |
|------------------------|--------------------------------------|--------------------|-----------------------------------------------------------------------------------|-----------------------|----------------------------------------------------------------------------------------|-----------------------------|---------------------------------------------------------------------------------|
| Bennie et al. (101) USA | Cross-sectional data analyses from health surveillance surveys (2011–2017). | n=1,477,981 adults (≥18 years), n=286,325 (18.0%) had depression. | Self reported physical activity survey. Physical activity was classified as aerobic and non-aerobic, and moderate intensity or vigorous intensity. | Not reported | Body Mass Index, Diabetes, Hypertension, Arthritis, Subjects were analyzed in stratified subgroups to reduce confounders. AL outcomes were not reported. | A total of 870 incident cases of depression | Lowest prevalence of depression was shown for those combining aerobic physical activity, or muscle strengthening activities, ≥2 days/week. |
| Fernandez-Montero et al. (102) Spain | Prospective study of physical activity and risk of depression | n=15,488 adults, follow-up of 10.5 years. | Leisure physical activity questionnaire (hours/week). | Not reported | Hypertension, Diabetes mellitus, Weight (Analyzed as confounders), Body mass index, Fat mass index, Waist circumference, C-reactive protein, IL-6 | A bidirectional association between obesity and depression was found. The effect of obesity on depression was more consistent than on anxiety. | Participants with higher total leisure physical activity exhibited a lower risk of depression. |
| Gomes et al. (23) Brazil | Prospective study of adiposity, inflammatory markers, depression and anxiety | n=2,977 Cohort followed-up from birth until 18 and 22 years old | International Physical Activity Questionnaire (IPAQ) | No | | | |
| Harvey et al. (100) Norway | Prospective study about exercise and the prevention of depression. | n=33,908 Cohort of healthy adults were followed for 11 years. | Validated questioners of exercise. | No | Body Mass Index, resting pulse. Less exercise at baseline was associated with higher resting pulse. | 22,564 individuals followed up, 1,578 (7.0%) developed depression and 1,972 (8.7%) anxiety. | Regular leisure-time exercise of any intensity provided protection against future depression but not anxiety. |
| Herbstlieb et al. (104) Germany | Cardio-respiratory fitness and autonomic function in patients with major depressive disorder | n=34 patients with depression and normal controls | International Physical Activity Questionnaire (IPAQ) | Conventional treatments (Antidepressants) | Heart rate, blood pressure, body fat, body mass index, Cardiopulmonary exercise test. | A negative correlation between depression and the IPAQ was found in patients with depression. | A lower fitness level in cardiopulmonary exercise test was observed in patients with depression. |
| Kerling et al. (105) Germany | Adjunctive exercise in depression: a randomized pilot trial | n=42 consecutive inpatients with major | Training program; three sessions per week, 45 minutes, moderate intensity compared to a | Psychotherapy (100%) and antidepressants (75-77%) | Exercise group showed lower heart rate, diastolic blood pressure, waist circumference, and higher | A negative correlation between depression and the IPAQ was found in patients with depression. | Exercise improves the outcome of inpatient treatment of moderate to severe depression. |

(Continued)
suggesting that adiposity may play a more substantial role in inflammation in women (106). Although these preliminary findings are promising, larger and adequately powered randomised controlled trials are needed to better evaluate the combined effect of physical activity and classical treatments on allostatic load and on depression and anxiety.

**Yoga Practice**

In the last years, yoga has become popular in western cultures and constitutes an interesting tool for stress management. Although yoga originated in India, different yoga styles are practiced in western societies at present. Most of the different styles contain physical postures (termed *asana* in Sanskrit), as well as breath control exercises (*pranayama*) and meditation (*dyana*) (113). A meta-analysis of randomised controlled trials performed on healthy subjects and on patients with medical conditions (e.g. cardiopathy, hypertension, metabolic syndrome, obesity, breast cancer), showed that yoga practice may reduce physiological measures of stress, including cortisol, autonomic measures (systolic blood pressure, heart rate), cytokines, and lipid levels (21). Also, yoga practice showed positive effects on depression and on anxiety in diverse patient populations (21, 120, 121) reducing depression and on anxiety symptoms in pregnant women (114), improved the mood states in psychiatric inpatients (115) and had beneficial effects on depression outcome in patients with major depressive disorder (116–118).

Regarding AL parameters, attenuated and decreased levels of salivary cortisol after yoga practice were reported in clinical trials on healthy patients (107, 108). These results correlated with lower perceived stress and negative affect (108) and with better cognitive functions, lower self-reported stress, and minor anxiety levels (107) (Table 2). Clinical evidences showed that yoga *asanas* can modulate the autonomic nervous system inducing higher parasympathetic activity, lower blood pressure, lower heart rate, higher relaxation and approach behaviors (21, 119). In a recent study using magnetic resonance spectroscopy yoga practice has been associated to higher GABA levels in depressed inpatients (116–118).

### Table 2: Yoga (Hatha Yoga/asanas)

| Study | Type of study | Study participants | Physical activity | Concomitant treatment | AL parameters measured | Depression/Anxiety outcome | Main conclusion |
|-------|---------------|-------------------|------------------|-----------------------|------------------------|---------------------------|-----------------|
| Gothe et al. (107) USA | A randomized control study | n = 118 healthy adults | An 8-week yoga intervention or a stretching control group. | No | Salivary cortisol | Executive functions, self-reported stress and anxiety | Yoga participants showed improvement in executive functions and showed an attenuated cortisol response. |
| West et al. (108) USA | Effects of hatha yoga and African dance on perceived stress and affect. | 69 healthy undergraduate students. | Different interventions in 3 groups of patients: African dance, hatha yoga, and biology lecture (control group). | No | Salivary cortisol levels were decreased in yoga group. | Perceived Stress, Affect (positive and negative affect schedule). | African dance and hatha yoga significantly decreased perceived stress and negative affect, compared to the biology class. |

**Table 2 | Continued**

| Study | Type of study | Study participants | Physical activity | Concomitant treatment | AL parameters measured | Depression/Anxiety outcome | Main conclusion |
|-------|---------------|-------------------|------------------|-----------------------|------------------------|---------------------------|-----------------|
| Philippot et al. (109) Belgium | A pilot randomised trial of physical exercise on depression and anxiety symptoms | n = 27 Healthy pre-adolescents age 9-11 years | Group with usual treatment 5-week period of intensive or low-to moderate exercises, four times a week. | No | Body mass index, body fat. No significant differences were found after treatment. Weight. No AL outcomes were measured. | A significant reduction in depression symptoms scores was observed in the exercise group. | The program focused on associating movement with pleasure, encouraged positive and non-competitive interactions between participants. |
| Schuch et al. (103) Brazil | Effects of aerobic physical exercise as an add-on strategy; A randomized controlled trial | n = 26 Severe depressed inpatients. | Aerobic physical exercise 16.5 kcal/kg/week, three times a week | Conventional treatments (pharmacotherapy and/or electroconvulsive therapy) | No | | |
| Valentine et al. (106) USA | Effects of yoga on executive function and stress | n = 127 community-dwelling older adults | Physical Activity Scale for the Elderly (PASE) | | | | |

**Yoga (Hatha Yoga/asanas)**

Although yoga originated in India, different yoga styles are practiced in western societies at present. Most of the different styles contain physical postures (termed *asana* in Sanskrit), as well as breath control exercises (*pranayama*) and meditation (*dyana*) (113). A meta-analysis of randomised controlled trials performed on healthy subjects and on patients with medical conditions (e.g. cardiopathy, hypertension, metabolic syndrome, obesity, breast cancer), showed that yoga practice may reduce physiological measures of stress, including cortisol, autonomic measures (systolic blood pressure, heart rate), cytokines, and lipid levels (21). Also, yoga practice showed positive effects on depression and on anxiety symptoms in pregnant women (114), improved the mood states in psychiatric inpatients (115) and had beneficial effects on depression outcome in patients with major depressive disorder (116–118). Regarding AL parameters, attenuated and decreased levels of salivary cortisol after yoga practice were reported in clinical trials on healthy patients (107, 108). These results correlated with lower perceived stress and negative affect (108) and with better cognitive functions, lower self-reported stress, and minor anxiety levels (107) (Table 2). Clinical evidences showed that yoga *asanas* can modulate the autonomic nervous system inducing higher parasympathetic activity, lower blood pressure, lower heart rate, higher relaxation and approach behaviors (21, 119). In a recent study using magnetic resonance spectroscopy yoga practice has been associated to higher GABA levels in depressed inpatients (116–118). A combination of body awareness-yoga *asanas* and mindfulness meditation has been developed in a complete program for stress reduction (21) and has been proposed to clinicians as a safe and effective technique to reduce stress and anxiety in diverse patient populations (21, 120, 121) reducing depression and on anxiety symptoms in pregnant women (114), improved the mood states in psychiatric inpatients (115) and had beneficial effects on depression outcome in patients with major depressive disorder (116–118).
stress, anxiety and depression, increasing the quality of life and well-being (107, 122–124). Yoga practice effectively decreases depressive and anxious symptomatology, although the neurobiological mechanisms involved are not totally elucidated (21). Regarding brain effects, neuroimaging studies demonstrated that hippocampus is activated during yoga practice (113, 125, 126). Moreover, a significantly greater hippocampal volume has been found in experienced yoga practitioners (113, 126, 127) and higher volumetric measures in different brain areas were positively correlated with the years of yoga practice (113).

CONCLUSIONS
Non-pharmacological interventions such as physical activity and yoga practice may exert synergizing effects to antidepressant and anxiolytic treatments. The classical treatment of patients with anxiety disorders and depression is psychotherapy, but pharmacotherapy is recommended when psychiatric symptoms are severe enough to induce a significant functional impairment (86). Antidepressants and/or benzodiazepines are indicated (National for Health and Clinical Excellence, UK guidelines) to treat these disorders (86). However, pharmacological treatments may be associated with adverse side effects. Physical activity and yoga practice have been shown to elicit improvements in anxiety and depression symptoms conducting to a better social, physical, and affective well-being optimizing the pharmacological treatment duration and the risk of pharmacological adverse side effects. However, larger and adequately powered randomized controlled trials are needed to evaluate the combined effect of physical activity on allostatic load and on depression and anxiety. Also, it is important to emphasize that future studies are needed to reveal the biological mechanisms involved in the therapeutic actions of physical activity and yoga, in particular on depression and anxiety. Furthermore, stratified interventions according to sex and age should be considered in the future to track the therapies toward an individualized schedule in agreement with the current medical practice.

REFERENCES
1. McEwen B, Stellar E. Stress and the individual. Mechanisms leading to disease. Arch Intern Med (1993) 27(153):2093–101. doi: 10.1001/archinte.153.18.2093
2. Seeman T, Epele E, Gruenewald T, Karlamangla A, McEwen BS. Socio-economic differentials in peripheral biology: cumulative allostatic load. Ann N Y Acad Sci (2010) 1186:223–39. doi: 10.1111/j.1749-6632.2009.05341.x
3. Suvarna B, Suvarna A, Phillips R, Juster RP, McDermott B, Sarnyai Z. Health risk behaviours and allostatic load: A systematic review. Neurosci Biobehav Rev (2020) 108:694–711. doi: 10.1016/j.neubiorev.2019.12.020
4. McEwen BS. Stress, adaptation, and disease. Allostasis and allostatic load. Ann N Y Acad Sci (1998) 840:33–44. doi: 10.1111/j.1749-6632.1998.tb09546.x
5. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res (2000) 866(1–2):172–89. doi: 10.1016/S0006-8993(00)02950-4
6. Crimmins EM, Johnston M, Hayward M, Seeman T. Age differences in allostatic load : an index of physiological dysregulation. Exp Gerontol (2003) 38:731–4. doi: 10.1016/S0531-5565(03)00099-8
7. Seeman TE, Crimmins E, Huang MH, Singer B, Bucur A, Gruenewald T, et al. Cumulative biological risk and socio-economic differences in mortality: MacArthur Studies of Successful Aging. Soc Sci Med (2004) 58:1985–97. doi: 10.1016/S0277-9536(03)00402-7
8. Juster R, McEwen BS, Lupien SJ. Neuroscience and Biobehavioral Reviews Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci Biobehav Rev (2010) 35(1):2–16. doi: 10.1016/j.neubiorev.2009.10.002
9. McEwen BS. Mood disorders and allostatic load. Biol Psychiatry (2003) 54 (3):200–7. doi: 10.1016/S0006-3223(03)00177-X
10. McEwen BS. Neurobiological and Systemic Effects of Chronic Stress. Chronic Stress (2017) 1:1–17. doi: 10.1177/2470547017692328
11. Juster RP, Sasseville M, Giguère CE., Consortium S, Lupien SJ. Elevated allostatic load in individuals presenting at psychiatric emergency services. J Psychosom Res (2018) 115:101–9. doi: 10.1016/j.jpsychores.2018.10.012
12. Soria CA, Remedi C, Núñez D, D’Alessio L, Roldán EJ. Impact of alprazolam in allostatic load and neurocognition of patients with anxiety disorders and chronic stress (GEMA): observational study protocol. BMJ Open (2015) 5:e007231. doi: 10.1136/bmjopen-2014-007231
13. de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci (2005) 6:646–75. doi: 10.1038/nrn1683
14. Swaab DF, Rao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev (2005) 4(2):141–94. doi: 10.1016/j.arr.2005.03.003
15. Lucassen P, Meerlo P, Naylor A, Dm AMV, Dayer A, Fuchs E, et al. Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action. Eur Neuropsychopharmacol (2010) 20(1):1–17. doi: 10.1016/j.euroepneuro.2009.08.003
16. McEwen BS, Gianaros PJ. Stress- and allostatic-induced brain plasticity. Am J Phys Med (2011) 90:431–45. doi: 10.1016/j.amjmedmedsci.052209-100430
17. Santarelli L, Saxe M, Cross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of Hippocampal Neurogenesis for the Behavioral Effects of Antidepressants. Sci (80– ). (2003) 301:805–9. doi: 10.1126/science.1083328
18. Mahar I, Bambico FR, Mechawar N, Nobrega JN, Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. Neurosci Biobehav Rev (2014) 38:173–92. doi: 10.1016/j.neubiorev.2013.11.009
19. Kandola A, Hendriks J, Lucassen PJ, Yücel M, Nolan Y. Aerobic Exercise as a Tool to Improve Hippocampal Plasticity and Function in Humans: Practical Implications for Mental Health Treatment. Front Hum Neurosci (2016) 10:1–25. doi: 10.3389/fnhum.2016.00373
20. Morres ID, Hatzigiorgeiadis A, Stathi A, Comoutos N, Arpin-Cribbie C, Krommidas C, et al. Aerobic exercise for adult patients with major depressive disorder in mental health services: A systematic review and meta-analyses. Depress Anxiety (2019) 36(1):39–53. doi: 10.1002/da.22842
21. Pascoe MC, Thompson DR, Ski CF. Yoga, mindfulness-based stress reduction and stress-related physiological measures: A meta-analysis.
D’Alessio et al. Reducing AL Depression and Anxiety Disorders

24. McEwen BS. Stressed or stressed out: what is the difference? J Psychiatry Neurosci (2005) 30(5):315–8. doi: 10.1111/j.1328-9366.2005.00347.x

25. Danese A, McEwen BS. Adverse childhood experiences, allostasis, allostatic load, and age-related disease. Physiol Behav (2012) 106(1):29–39. doi: 10.1016/j.physbeh.2011.08.019

29. Rodriquez EJ, Sabado-Liwag M, Pe

30. Bey G, Jesdale B, Ulbricht C, Mick E, Person S. Allostatic Load Biomarker healthcare6030105

34. de Kloet ER, McEwen BS. Previous history of chronic stress changes the region of the male rat hippocampus. Proc Natl Acad Sci U S A (1997) 94:14002–8. doi: 10.1073/pnas.94.25.14002

35. Datson NA, Van Den Oever JME, Korobko OB, Magarinos AM, De Kloet ER, et al. Characterization of allostatic overload. Psychoneuroendocrinology (2019) 109:104369. doi: 10.1016/j.psyneuen.2019.06.020

36. Gallagher P, Young AH. Mifepristone (RU-486) treatment for depression: an open label trial of C-1073 (mifepristone) for psychotic major depression. Am J Psychiatry (2007) 163:697–704. doi: 10.1176/ajp.2007.163.6.697

40. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and possible mediators. Rev Saude Publica (2019) 53:103. doi: 10.11606/S1518-8787.2019053001119

41. Vancampfort D, Correll CU, Wampers M, Sienra P, Mitchell AJ, De Herdt A, et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: A meta-analysis of prevalence and moderating variables. Psychol Med (2014) 44(10):2073–28. doi: 10.1017/s0033291713002773

42. Wedekind D RE, Bandelow B, Broocks A, Hajak G. Salivary, total plasma and plasma free cortisol in panic disorder. J Neurotransm (2000) 107 (7):831–7. doi: 10.1016/s0022-2828(00)00111-8

43. Martella RC, Butters MA, Amico JA, Mazumdar S, Rollman BL, Begley AE, et al. Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology (2008) 33(6):773–81. doi: 10.1016/j.psyneuen.2008.03.002

44. Yang Y, Koolen S. Markers in the assessment of depression in a population of healthy adults. Front Psychiatry (2017) 8:127. doi: 10.3389/fpsyt.2017.00127

45. Schöberl W, Miltner WH, Koller W, Penzlin T, Mergel T, et al. Stress-related differences in cortical thickness and functional activation: A positron emission tomography (PET) study in major depressive disorder (MDD) and control subjects. Psychiatry Res (2006) 150(3):295–308. doi: 10.1016/j.psychres.2006.07.010

46. Wang Q, Liang H, Zeng W, Wang X, Zhang H, et al. Combined effect of anxiety and depression on hospitalization costs in patients with chronic obstructive pulmonary disease: A propensity score matching study. J Affect Disord (2019) 251:236–43. doi: 10.1016/j.jad.2019.01.033

47. Sramek JJ, Murphy MF, Cutler NR. Sex differences in the neuropharmacological treatment of depression. Dialogues Clin Neurosci (2016) 18(4):477–57.

48. Verma CS, Balbarr YPS, Gupta. Gender differences in stress response: Role of developmental and biological determinants. Ind Psychiatry J (2011) 20(1): 4. doi: 10.4103/0972-6748.98407

49. Scóvola I, Tettelbaum J, Oddo S, Centurion E, Loidl CF, Kochen S, et al. Psychiatric disorders in patients with psychogenic nonepileptic seizures and drug-resistant epilepsy: a study of an Argentine population. Epilepsy Behav (2013) 29(1):155–60. doi: 10.1016/j.yebeh.2013.07.012

50. Brown TC, Baskin-Sommers CA, Nezamis KE, Shih Y, Al-Imam FO. Stress hormone profiles in human subjects: a meta-analysis. Horm Behav (2012) 61(3):469–79. doi: 10.1016/j.yhbeh.2011.12.001

51. Zonderman AB. The role of stress in the development of late life depression and cognitive function: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci (2011) 66(1):1–12. doi: 10.1093/gerona/glr003

52. Juster RP, Pruessner JC, Desrochers AB, Bourdon O, Durand N, Wan W, et al. Sex and Gender Roles in Relation to Mental Health and Allostatic Load. Psychosom Med (2016) 78(7):788–804. doi: 10.1097/PSY.0000000000000351

53. Soria CA, Remedi C, D’Alessio L, Rolda MC, Wehrmeister FC, Gregorich SE, et al. Allostatic Load, Unhealthy Behaviors, and Depressive Symptoms by Birthplace Among Older Adults in the Sacramento Area Latino Study on Aging (SALSA). J Aging Health (2019) 22:1–18. doi: 10.1177/0898264119857995

54. Jensen KM, Gluud C, Overvad K, Tjonneland A, Overvad J, et al. Antidepressants and the risk of breast cancer: a systematic review and meta-analysis. JAMA Oncol (2016) 2(1):33–40. doi: 10.1001/jamaoncol.2015.5216

55. Eriksson PS, Peres-Stable EJ, Lee A, Haan MN, Shi Q, Kiecolt-Glaser JK, et al. Stress, depression and hippocampal apoptosis. Brain Behav Immun (2005) 19(6):561–6. doi: 10.1016/j.bbi.2005.03.010

56. Lucassen PJ, Heine VM, Muller MB, van der Beek EM, Wiegant VM, De Kloet ER, et al. Stress, depression and hippocampal apoptosis. CNS Neurosci Ther (2019) 25(8):509–16. doi: 10.1111/cnst.12813

57. Sahay A, Drew MR, Hen R. Dentate gyrus neurogenesis and depression. Brain Res Bull (2008) 76(7):851–7. doi: 10.1016/j.brainresbull.2008.07.006

58. Belanoff JK, Joels M, Milaneschi Y, Hong X, Hen R, et al. Meta-analysis of age differences in hippocampal neurogenesis in mice. Hippocampus (2017) 27(4):458–67. doi: 10.1002/hipo.24944

59. Samuels BA, Murakami A, Usui Y, et al. Chronic stress inhibits the glucocorticoid-induced neuronal death of CA1 hippocampal pyramidal neurons. J Neurosci (2010) 30(27):9064–75. doi: 10.1523/JNEUROSCI.2338-10.2010

60. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with bipolar disorder. J Neurosci (2006) 26(39):9929–37. doi: 10.1523/JNEUROSCI.2338-10.2010

61. Vancampfort D, Correll CU, Wampers M, Sienra P, Mitchell AJ, De Herdt A, et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: A meta-analysis of prevalence and moderating variables. Psychol Med (2014) 44(10):2073–28. doi: 10.1017/s0033291713002773

62. Wedekind D RE, Bandelow B, Broocks A, Hajak G. Salivary, total plasma and plasma free cortisol in panic disorder. J Neurotransm (2000) 107 (7):831–7. doi: 10.1016/s0022-2828(00)00111-8

63. Martella RC, Butters MA, Amico JA, Mazumdar S, Rollman BL, Begley AE, et al. Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology (2008) 33(6):773–81. doi: 10.1016/j.psyneuen.2008.03.002
recent major depression. *J Neurosci* (1999) 19(12):5034–43. doi: 10.1523/JNEUROSCI.19-12-05034.1999

61. Treadway MT, Wasko DL, Dillon DG, Holmes AJ, Park MTM, Chakravarty MM, et al. Archival Report Illness Progression, Recent Stress, and Morphometry of Hippocampal Sub fields and Medial Prefrontal Cortex in Major Depression. *Biol Psychiatry* (2015) 77(3):285–94. doi: 10.1016/j.biopsych.2014.06.018

62. Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. *Biol Psychiatry* (1999) 46(12):1595–602. doi: 10.1016/S0006-3223(99)00260-3

63. Yehuda R. Advances in understanding neuroendocrine alterations in PTSD and their therapeutic implications. *Ann NY Acad Sci* (2006) 1071:137–66. doi: 10.1196/annals.1364.012

64. D’Alessio L, Konopka H, Solis P, Scévola L, Lima MF, Núñez C, et al. Depression and Temporal Lobe Epilepsy: Expression Pattern of Calbindin Immunoreactivity in Hippocampal Dentate Gyrus of Patients Who Underwent Epilepsy Surgery with and without Comorbid Depression. *Behav Neurol* (2019) 2019:1–12. doi: 10.1155/2019/739679

65. D’Alessio L, Konopka H, Escobar E, Acuña A, Oddo S, Solis P, et al. Dentate gyrus expression of nestin-immunoreactivity in patients with drug-resistant temporal lobe epilepsy and hippocampal sclerosis. *Seizure* (2015) 27:55–9. doi: 10.1016/j.seizure.2015.02.008

66. Monaghan MA, Wheeler MA, Surjadi JS, Stadel RP, Sun GJ, Ming GL, et al. In vivo clonal analysis reveals self-renewing and multipotent adult neural stem cell characteristics. *Cell* (2011) 145(7):1142–55. doi: 10.1016/j.cell.2011.05.024

67. Lugert S, Basak O, Knuckles P, Haussler U, Fabel K, Götz M, et al. Quiescent and active hippocampal neural stem cells with distinct morphologies respond selectively to physiological and pathological stimuli and aging. *Cell Stem Cell* (2010) 6(5):445–56. doi: 10.1016/j.stem.2010.03.017

68. Anacker C, Hen R. Adult hippocampal neurogenesis and cognitive flexibility-linking memory and mood. *Nat Publ Gr* (2017) 18:335–46. doi: 10.1038/nrn.2017.45

69. Chen H, Lombés M, Le Menuet D. Glucocorticoid receptor represses brain-derived neurotrophic factor expression in neuron-like cells. *Mol Brain* (2017) 10(12):1–10. doi: 10.1186/s13041-017-0295-x

70. Taliz D, Stall N, Dar D, Zangen A. Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neuroplasticity. *Mol Psychiatry* (2010) 15(1):80–92. doi: 10.1038/mp.2009.67

71. Lakshminaraisanam H, Chattarji S. Stress leads to contrasting effects on the levels of brain derived neurotrophic factor in the hippocampus and amygdala. *PloS One* (2012) 7(1):1–6. doi: 10.1371/journal.pone.0030481

72. Mahberg JE, Eisich AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J Neurosci* (2000) 20(24):9104–10. doi: 10.1523/JNEUROSCI.20-24-09104.2000

73. Čebz B, Michaelsen T, Watanabe T, Frahm J, van Kampen M, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, amygdala.

74. Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis: Opposing effects of stress and antidepressant treatment. *Hippocampus* (2006) 16 (3):239–49. doi: 10.1002/hipo.20156

75. Van Den Berg F, Tulen JHM, Boomsma F, Noten JGBM, Moleman P, Peppinlkhuizen E. Effects of alprazolam and lorazepam on catecholaminergic and cardiovascular activity during supine rest, mental load and orthostatic challenge. *Psychopharmacol (Berl)* (1996) 128:21–30. doi: 10.1007/s002130050105

76. Van KR LC, Rudolph U. Hooke don benzodiazepines: GABAA receptor subtypes and addiction. *Trends Neurosci* (2011) 34:188–97. doi: 10.1016/ j.tins.2011.01.004

77. Curtis GC, Abeleon JL, Gold PW. Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. *Biol Psychiatry* (1997) 41(1):76–85. doi: 10.1016/S0006-3223(95)00578-1

78. Zemishlany Z RM, McQueeney R, Gabriel SR. Neuroendocrine and monoaminergic responses to acute administration of alprazolam in normal subjects. *Neuropsychobiology* (1990) 23(3):124–8. doi: 10.1159/000119437

79. Yilmaz S, Pekdemir M, Tural U, Uygur M. Comparison of alprazolam versus captopril in high blood pressure: a randomized controlled trial. *Blood Press Monit* (2011) 20(2):93–4. doi: 10.1093/ibp/brs115

80. Hoge EA, Jovicic A, Frischhion GL. Generalized anxiety disorder : diagnosis and treatment. *BMJ* (2012) 345:e7500. doi: 10.1136/bmj.e7500

81. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. *Arch Clin Neuropsychol* (2019) 4(3):437–54. doi: 10.1007/s002130050009-6

82. Billioti S, Gage D, Bégaud B, Bazin F. Benzodiazepine use and risk of dementia : prospective population based study. *BMJ* (2012) 345:e2631–e6231. doi: 10.1136/bmj.e6231

83. Soria CA, Remedi C, D’Alessio L, Roldán EJ. Semantic and Phonemic Verbal Fluency Performance in Patients with General Anxiety Disorders and Allostatic Load under Alprazolam Treatment. *Open Psychiatry J* (2019) 9 (2):138–52. doi: 10.4236/oppsycho.2019.92011

84. Brown J, Cooper-Kuhn CM, Kempermann G, Van Praag H, Winkler J, Gage FH, et al. Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis. *Eur J Neurosci* (2003) 17(10):2042–6. doi: 10.1046/j.1460-9586.2003.02647.x

85. Vaynman S, Ying Z, Gomez-Pinilla F. Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. *Eur J Neurosci* (2012) 35(2):5–14. doi: 10.1111/j.1460-9586.2011.07353.x

86. Russo E, Citraro R, Sciccitano F, Urzino A, Marra R, Rispoli V, et al. Rapamycin but not celecoxib prevents memory impairment in hippocampal memory task. *Neuropharmacology* (2012) 62:130–41. doi: 10.1016/j.neuropharm.2011.10.003

87. D’Alessio et al. Reducing AL Depression and Anxiety Disorders.
Reducing AL Depression and Anxiety Disorders

derived neurotrophic factor (BDNF): A systematic review of experimental studies in the elderly. Arch Gerontol Geriatr (2013) 56(1):10–5. doi: 10.1016/j.archger.2012.06.003

99. Pascoe M, Bailey AP, Craike M, Carter T, Patten R, Septo N, et al. Physical activity and exercise in youth mental health promotion: A scoping review. BMJ Open Sport Exerc Med (2020) 6(1):11–1. doi: 10.1136/bmjsem-2019-000677

100. Harvey SB, Overland S, Hatch SL, Wessely S, Myklebust A, Hotopf M. Exercise and the prevention of depression: Results of the HUNT cohort study. Am J Psychiatry (2018) 175(1):28–36. doi: 10.1176/appi.ajp.2017.16111223

101. Bennie JA, De Cocker K, Biddle SJH, Teychenne MJ. Joint and dose-dependent associations between aerobic and muscle-strengthening activity with depression: A cross-sectional study of 1.48 million adults between 2011 and 2017. Depress Anxiety (2020) 37(2):166–78. doi: 10.1002/da.22986

102. Fernandez-Montero A, Moreno-Galarraga L, Sanchez-Villegas A, Lahortiga-Ramos F, Ruiz-Canela M, Martinez-Gonzalez MA, et al. Dimensions of leisure-time physical activity and risk of depression in the ‘seguimiento Universidad de Navarra’ (SUN) prospective cohort. BMC Psychiatry (2020) 20(1):1–9. doi: 10.1186/s12888-020-02549-5

103. Schuch FB, Vasconcelos-Moreno MP, Borowczyk C, Fleck MP. Exercise and severe depression: Preliminary results of an add-on study. J Affect Disord (2011) 133(3):615–8. doi: 10.1016/j.jad.2011.04.030

104. Herbsleb M, Schumann A, Lehmann L, Gabriel HHW, Bär KJ. Cardio-Respiratory Fitness and Autonomic Function in Patients with Major Depressive Disorder. Front Psychiatry (2020) 10:1–10. doi: 10.3389/fpsyt.2020.00980

105. Kerling A, Tegrbur U, Gützlaff E, Kück M, Borchert L, Ates Z, et al. Effects of adjunctive exercise on physiological and psychological parameters in depression: A randomized pilot trial. J Affect Disord (2015) 177:1–6. doi: 10.1016/j.jad.2015.01.006

106. Valentine RJ, McAuley E, Vieira VJ, Baynard T, Hu L, Evans EM, et al. Sex differences in prevalence of obesity, C-reactive protein, physical activity, depression, sleep quality and fatigue in older adults. Brain Behav Immun (2009) 23(5):643–8. doi: 10.1016/j.bbi.2008.12.003

107. Gothe NP, Keswani RK, McAuley E. Yoga practice improves executive function by attenuating stress levels. Biol Psychol (2016) 121:109–16. doi: 10.1016/j.biopsycho.2016.10.010

108. West J, Otte C, Geher K, Johnson J, Mohr DC. Effects of Hatha yoga and meditation practitioners. Ann Behav Med (2004) 28(2):114–8. doi: 10.1207/s15324796abm2802_6

109. Philippot A, Meerschaut A, Danneux I, Smal G, Bleyenheuft Y, De Volder AG. Impact of physical exercise on symptoms of depression and anxiety in pre-adolescents: A pilot randomized trial. Front Psychol (2019) 10:1–11. doi: 10.3389/fpsyg.2019.01820

110. Schuch FB, Stubbs B, Meyer J, Heissel A, Zech P, Vancampfort D, et al. Physical activity protects from incident anxiety: A meta-analysis of prospective cohort studies. Depress Anxiety (2019) 36(9):846–58. doi: 10.1002/da.22915

111. Bernard P, Romain AJ, Caudroit J, Chevance G, Carayol M, Gourlan M, et al. Cognitive behavior therapy combined with exercise for adults with chronic diseases: Systematic review and meta-analysis. Heal Psychol (2018) 37(5):433–50. doi: 10.1037/hea0000578

112. Valentine RJ, Vieira VJ, Woods JA, Evans EM. Stronger relationship between central adiposity and C-reactive protein in older women than men. Menopause (2009) 16(1):84–9. doi: 10.1097/gme.0b013e318176cb8f

113. Villemure C, Ćeko M, Cotton VA, Catherine Bushnell M. Neuroprotective effects of yoga practice: Age-, experience-, and frequency-dependent plasticity. Front Hum Neurosci (2015) 9(281):1–12. doi: 10.3389/fnhum.2015.00281

114. Newham JJ, Wittkowski A, Hurley J, Aplin JD, Westwood M. Effects of antenatal yoga on maternal anxiety and depression: A randomized controlled trial. Depress Anxiety (2014) 31(8):631–40. doi: 10.1002/da.22268

115. Lavey R, Sherman T, Mueser KT, Osborne DD, Currier M, Wolfe R. The Effects of Yoga on Mood in Psychiatric Inpatients. Psychiatr Rehabil J (2005) 28(4):399–402. doi: 10.2975/28.2005.399.402

116. Uebelacker LA, Tremont G, Epstein-Lubow G, Gaudiano BA, Gillette T, Kalibataeva Z, et al. Open trial of Vinyasa yoga for persistently depressed individuals: Evidence of feasibility and acceptability. Behav Modif (2010) 34(3):247–64. doi: 10.1177/0145445510368845

117. Cramer H, Anheyer D, Lauche R, Dobos G. A systematic review of yoga for major depressive disorder. J Affect Disord (2017) 213(2016):70–7. doi: 10.1016/j.jad.2017.02.006

118. Streeter CC, Gerbarg PL, Brown RP, Scott TM, Nielsen GH, Owen L, et al. Thalamic Gamma Aminobutyric Acid Level Changes in Major Depressive Disorder After a 12-Week Iyengar Yoga and Coherent Breathing Intervention. J Altern Complement Med (2020) 26(3):190–7. doi: 10.1089/acm.2019.0234

119. Ross A, Thomas S. The health benefits of yoga and exercise: A review of comparison studies. J Altern Complement Med (2010) 16(1):3–12. doi: 10.1089/acm.2009.0044

120. Kuyken W, Warren FC, Taylor RS, Whalley B, Crane C, Bondolfi G, et al. Efficacy of mindfulness-based cognitive therapy in prevention of depressive relapse an individual patient data meta-analysis from randomized trials. JAMA Psychiatry (2016) 73(6):565–74. doi: 10.1001/jamapsychiatry.2016.0076

121. Korman GP, Garay CJ. El modelo de Terapia Cognitiva Basada en la Conciencia Plena ( mindfulness ). Ecco (2012) XXX:5–13

122. Kirkwood G, Rampes H, Tuffrey V, Richardson J, Pilkington K. Yoga for anxiety: A systematic review of the research evidence. Br J Sports Med (2005) 39(12):884–91. doi: 10.1136/bjsm.2005.018069

123. Shapiro SL, Brown KW, Biegel GM. Teaching self-care to caregivers: Effects of mindfulness-based stress reduction on the mental health of therapists in training. Train Educ Psychol (2007) 1(2):105–15. doi: 10.1037/1931-3918.1.2.105

124. Oken BS, Zajdel D, Kishiya S, Flegel K, Dehen C, Haas M, et al. Randomized, controlled, six-month trial of yoga in healthy seniors: Effects on cognition and quality of life. Altern Ther Health Med (2006) 12(1):40–7.

125. Lazar SW, Bush G, Collub GL, Frischione GL, Khalsa G, Benson H. Functional brain mapping of the relaxation response and meditation. Neuroreport (2000) 11(7):1581–5. doi: 10.1097/00001756-200005150-00042

126. Holzel BK, Lazar SW, Gard T, Schuman-Olivier Z, Vago DR, Ott U. How does mindfulness meditation work? Proposing mechanisms of action from a conceptual and neural perspective. Perspect Psychol Sci (2011) 6(6):537–59. doi: 10.1177/1745691611419671

127. Luders E, Thompson PM, Kurth F, Hong JY, Phillips OR, Wang Y, et al. Global and regional alterations of hippocampal anatomy in long-term meditation practitioners. Hum Brain Mapp (2013) 34(12):3369–75. doi: 10.1002/hbm.22153

Conflict of Interest: LD’A received a grant for participating in this project from Gador SA. AO, AP, and ER are employees of Gador SA.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 D’Alessio, Korman, Saradzansky, Guelman, Sicilia, Pastora, Obregón and Roldán. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.